Little House Capital’s United Therapeutics UTHR Stock Holding History

Little House Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-65	Closed	-$7K	–	258
2019 Q1	$7K	Buy	+65	New	+$7.57K	0.01%	265

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Little House Capital's UTHR Position: Q2 2019 in Review

Little House Capital sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 65 shares — an estimated $7K sold.

Little House Capital first reported a position in UTHR in Q1 2019 and held it in 1 quarter. The position peaked at $7K in Q1 2019. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

Little House Capital reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
Little House Capital sold 65 United Therapeutics shares in Q2 2019, an estimated $7K.
Little House Capital first reported a position in United Therapeutics in Q1 2019 and held it in 1 quarter.
Little House Capital's United Therapeutics position peaked at $7K in Q1 2019.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Little House Capital's 13F filing for Q2 2019, filed 14 Aug 2019.